Lilly Announces Changes in Senior Management

INDIANAPOLIS, Oct. 11, 2011 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY)
today announced key appointments due to the December 31 retirements of longtime
senior leaders, Bryce D. Carmine and Frank Deane, Ph.D.

Carmine, whose Lilly career spans 36 years, has led Lilly Bio-Medicines since
its creation in 2009. And Deane, whose career at Lilly spans 33 years, has led
global manufacturing operations since 2007. Previously, both held numerous
high-level leadership posts around the globe.

John C. Lechleiter, Ph.D., chairman, president, and chief executive officer,
described Carmine and Deane as “pillars of the company who have had a lasting,
worldwide impact on our people and our business. We’re grateful for their
dedicated service.”

Effective January 1:

— Dave Ricks, president of Lilly USA, is being promoted to succeed Carmine
as senior vice president and president of Lilly Bio-Medicines. Ricks
formerly was general manager of Lilly affiliates in China and Canada.
Ricks’ responsibilities will include the U.S., Japan, and Europe.
Bio-Medicines encompasses the therapeutic areas of neuroscience,
cardiovascular, autoimmunity, musculoskeletal, and urology.
— Maria Crowe, senior vice president for global drug product
manufacturing, is being promoted to succeed Deane as president of
manufacturing operations. She formerly was general manager of
manufacturing sites in Ireland and Puerto Rico. As head of manufacturing
operations, she will lead a network of 22 sites in 13 countries and also
will have responsibility for Lilly’s global contract-manufacturing
organization.
— Alex Azar, following Ricks’ promotion, is being promoted to president of
Lilly USA, the company’s largest affiliate. Azar has been vice president
of U.S. managed healthcare services and Puerto Rico since 2009. Azar
joined the company in 2007 as senior vice president of Lilly’s global
corporate affairs and communications division. Prior to joining Lilly,
he served as the Deputy Secretary of the U.S. Department of Health and
Human Services.

“We’ll certainly miss Bryce and Frank and the extraordinary leadership they
provided,” Lechleiter said. “At the same time, we’re very fortunate to have
talented leaders who are well-prepared and ready to step into these critical
roles.”

Additional details about the individuals involved in today’s announcements:

David Ricks, a 15-year Lilly veteran, has led three of Lilly’s most important
affiliates: the U.S., China, and Canada. As president of Lilly USA since 2009,
Ricks spearheaded a new operating model focused on increasing customer
satisfaction and sustaining revenue growth while preparing for patent losses and
significant changes to the health care system in the United States.

Ricks joined Lilly in 1996 as a business development associate and held several
management roles in U.S. marketing and sales before moving into key
international roles for seven years – most recently as president and general
manager of Lilly’s affiliate in China, one of the world’s fastest-growing
pharmaceutical markets. He previously served as general manager of Lilly Canada
after roles there as director of pharmaceutical marketing and national sales
director.

Ricks earned a bachelor’s degree in business from Purdue University and an MBA
from Indiana University. Prior to joining Lilly, Ricks held positions with
Hewlett-Packard Corp. and IBM.

Maria Crowe has served as senior vice president for global drug product
manufacturing since August 2009. In this role, she has overseen all of Lilly’s
drug product manufacturing, packaging, and distribution operations. This
includes sites that manufacture tablets and capsules as well as those that
manufacture sterile injectable products.

In her 29-year Lilly career, Crowe has held numerous roles in drug product and
active pharmaceutical ingredient (API) manufacturing, as well as in sourcing and
procurement. Prior to her current role, Crowe was vice president for drug
product manufacturing in the Americas (the United States and Latin America).
Crowe also served as general manager at Lilly’s Kinsale, Ireland, plant; general
manager of Lilly del Caribe in Puerto Rico; and plant manager of Lilly’s Elanco
manufacturing plant at the former Tippecanoe manufacturing site.

Crowe holds a bachelor’s degree in industrial management from Purdue University.

Alex Azar joined Lilly in 2007 as senior vice president of corporate affairs. In
2009, he became vice president of U.S. managed health care services and Puerto
Rico. In that role, he has led the company’s managed care, public payer,
hospital, wholesaler, and retailer operations in the United States as well as
Lilly’s sales and marketing operations in Puerto Rico.

Before joining the company, Azar served as the U.S. Deputy Secretary of Health
and Human Services (HHS), the largest civilian department in the federal
government. Before entering government, he was a partner at the Washington,
D.C., law firm of Wiley, Rein & Fielding. Azar earned a bachelor’s degree in
economics and government from Dartmouth College and is a graduate of Yale Law
School.

Bryce D. Carmine has led Lilly Bio-Medicines since September 2009, when the
company reorganized its pharmaceutical business into the operating model that
exists today. Carmine’s prior roles have included executive vice president of
global marketing and sales, president of global product development, president
of metabolic disorders and specialty products, and managing director in Japan.
He joined Lilly in 1975 as a sales representative in New Zealand.

Frank Deane, Ph.D., became president of global manufacturing operations in June
2007. He had been vice president of quality since December 2001. His previous
roles have included management in Ireland and Puerto Rico. He returned to the
United States in 1993 as general manager of U.S. pharmaceutical manufacturing
and assumed responsibility for Lilly’s worldwide API manufacturing operations in
1997. He joined Lilly in 1979 as a technical coordinator in manufacturing in
Indianapolis.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -
through medicines and information – for some of the world’s most urgent medical
needs. Additional information about Lilly is available at www.lilly.com. C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)

SOURCE Eli Lilly and Company